Consumer health giant Haleon is building its first oral health manufacturing site in China as part of a project investment agreement signed in Shanghai on March 13 by Haleon China and the Lin-gang Special Area Administration.

An aerial view of Lin-gang Special Area. [Photo/lingang.gov.cn]

Haleon, a British consumer health giant listed on both the London Stock Exchange and the New York Stock Exchange, has been operating in China for more than 40 years. The company's portfolio includes widely trusted brands such as Centrum, Caltrate, Advil, and Sensodyne.

The company announced an investment of approximately 65 million pounds ($86.6 million) to build an advanced oral health manufacturing site in Lin-gang. The site will primarily produce professional oral care products under the Sensodyne and Parodontax brands, with the aim of strengthening its supply chain through owned production capacity to meet growing Chinese consumer demand for premium oral care solutions.

Lin-gang Special Area is committed to building a world-class business environment that is market-oriented, rules-based, and internationally aligned. With its high degree of openness, efficient government services, well-developed industrial ecosystem, and a livable urban environment, Lin-gang is emerging as a preferred destination for global foreign investment.